J Endocrinol Metab

Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access

Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc

Journal website http://www.jofem.org

Original Article

Volume 2, Number 3, June 2012, pages 110-119

Effect of Telmisartan on Olanzapine Induced Metabolic Syndrome in Ovariectomized Female Sprague-Dawley Rats

Figure 1. Effect of telmisartan on blood glucose level. n = 6; The values are expressed as mean± SEM; ^**P < 0.01 when compared to normal control, ^$$P < 0.01 when compared to OVX and ^##P < 0.01 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). Group A: normal control, Group B: ovariectomy control, Group C: ovariectomy + olanzapine control, Group D: ovariectomy group treated with telmisartan, Group E: ovariectomy + olanzapine group treated with telmisartan.

Figure 2. Effect of telmisartan on plasma insulin level. n = 6; The values are expressed as mean ± SEM; ^**P < 0.01 when compared to normal control, ^$$P < 0.01 when compared to OVX and ^##P < 0.01 when compared to OVX +OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). Group A: normal control, Group B: ovariectomy control, Group C: ovariectomy + olanzapine control, Group D: ovariectomy group treated with telmisartan, Group E: ovariectomy + olanzapine group treated with telmisartan.

Figure 3. Effect of telmisartan on SGOT level. n =6; The values are expressed as mean ± SEM; ^**P <0.01 when compared to normal control, ^$P < 0.05 when compared to OVX and ^##P < 0.01 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). Group A: normal control, Group B: ovariectomy control, Group C: ovariectomy + olanzapine control, Group D: ovariectomy group treated with telmisartan, Group E: ovariectomy + olanzapine group treated with telmisartan.

Figure 4. Effect of telmisartan on SGPT level. n =6; The values are expressed as mean ± SEM; ^**P <0.01 when compared to normal control, ^$$P < 0.01 when compared to OVX and ^##P < 0.01 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). Group A: normal control, Group B: ovariectomy control, Group C: ovariectomy + olanzapine control, Group D: ovariectomy group treated with telmisartan, Group E: ovariectomy + olanzapine group treated with telmisartan.

**Table 1.** Effect of Telmisartan on Body Weight
Group	Treatment	Body weight (g)
n = 6; the values are expressed as Mean ± SEM; ^**P < 0.01 when compared to normal control, ^$P < 0.05 when compared to OVX and ^#P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). OVX: ovariectomy control, OVX + OLZ: ovariectomy + olanzapine control, OVX + TEL: ovariectomy group treated with telmisartan, OVX + OLZ + TEL: ovariectomy + olanzapine group treated with telmisartan.
A	Normal Control	211.67 ± 6.009	223.50 ± 6.087	11.833 ± 0.910
B	OVX Control	213.33 ± 9.545	233.83 ± 10.879	20.500 ± 2.432^**
C	OVX + OLZ Control	220.00 ± 11.255	242.16 ± 11.677	22.167 ± 2.242^**
D	OVX + TEL	225.00 ± 9.574	211.50 ± 10.052	13.500 ± 1.544^$
E	OVX + OLZ +TEL	220.00 ± 7.303	205.33 ± 7.401	14.667 ± 1.453^#

Table 1. Effect of Telmisartan on Body Weight

Group

Treatment

Body weight (g)

Initial

Final

Weight gain

n = 6; the values are expressed as Mean ± SEM; ^**P < 0.01 when compared to normal control, ^$P < 0.05 when compared to OVX and ^#P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). OVX: ovariectomy control, OVX + OLZ: ovariectomy + olanzapine control, OVX + TEL: ovariectomy group treated with telmisartan, OVX + OLZ + TEL: ovariectomy + olanzapine group treated with telmisartan.

Normal Control

211.67 ± 6.009

223.50 ± 6.087

11.833 ± 0.910

OVX Control

213.33 ± 9.545

233.83 ± 10.879

20.500 ± 2.432^**

OVX + OLZ Control

220.00 ± 11.255

242.16 ± 11.677

22.167 ± 2.242^**

OVX + TEL

225.00 ± 9.574

211.50 ± 10.052

13.500 ± 1.544^$

OVX + OLZ +TEL

220.00 ± 7.303

205.33 ± 7.401

14.667 ± 1.453^#

**Table 2.** Effect of Telmisartan on Total Cholesterol, Triglyceride, HDL-C, LDL-C and VLDL-C Levels
Group	Treatment	Total Cholesterol	Triglyceride	HDL-C	LDL-C	VLDL-C
n = 6; the values are expressed as Mean ± SEM; ^**P < 0.01 when compared to normal control, ^$$P < 0.01, ^$P < 0.05 when compared to OVX and ^##P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). OVX: ovariectomy control, OVX + OLZ: ovariectomy + olanzapine control, OVX + TEL: ovariectomy group treated with telmisartan, OVX + OLZ+TEL: ovariectomy + olanzapine group treated with telmisartan.
A	Normal Control	65.233 ± 1.67	58.917 ± 3.36	33.33 ± 1.25	20.00 ± 1.15	11.783 ± 0.67
B	OVX Control	77.83 ± 1.95^**	88.08 ± 4.76^**	26.66 ± 0.71^**	33.60 ± 1.1^**	17.61 ± 0.95^**
C	OVX + OLZ Control	82.03 ± 1.85^**	99.16 ± 3.27^**	23.93 ± 0.60^**	38.16 ± 1.24^**	19.83 ± 0.65^**
D	OVX + TEL	70.61 ± 1.01^$$	70.41 ± 3.83^$	35.60 ± 0.96^$$	20.43 ± 1.19^$$	14.083 ± 0.76^$
E	OVX + OLZ + TEL	74.23 ± 1.33^##	72.25 ± 6.26^##	37.95 ± 1.08^##	21.83 ± 0.98^##	14.45 ± 1.25^##

Table 2. Effect of Telmisartan on Total Cholesterol, Triglyceride, HDL-C, LDL-C and VLDL-C Levels

Group

Treatment

Total Cholesterol

Triglyceride

HDL-C

LDL-C

VLDL-C

n = 6; the values are expressed as Mean ± SEM; ^**P < 0.01 when compared to normal control, ^$$P < 0.01, ^$P < 0.05 when compared to OVX and ^##P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnett’s multiple comparison test). OVX: ovariectomy control, OVX + OLZ: ovariectomy + olanzapine control, OVX + TEL: ovariectomy group treated with telmisartan, OVX + OLZ+TEL: ovariectomy + olanzapine group treated with telmisartan.

Normal Control

65.233 ± 1.67

58.917 ± 3.36

33.33 ± 1.25

20.00 ± 1.15

11.783 ± 0.67

OVX Control

77.83 ± 1.95^**

88.08 ± 4.76^**

26.66 ± 0.71^**

33.60 ± 1.1^**

17.61 ± 0.95^**

OVX + OLZ Control

82.03 ± 1.85^**

99.16 ± 3.27^**

23.93 ± 0.60^**

38.16 ± 1.24^**

19.83 ± 0.65^**

OVX + TEL

70.61 ± 1.01^$$

70.41 ± 3.83^$

35.60 ± 0.96^$$

20.43 ± 1.19^$$

14.083 ± 0.76^$

OVX + OLZ + TEL

74.23 ± 1.33^##

72.25 ± 6.26^##

37.95 ± 1.08^##

21.83 ± 0.98^##

14.45 ± 1.25^##

**Table 3.** Effect of Telmisartan on Liver and Kidneys Weight
Group	Treatment	Liver weight	Kidney weight
n = 6; The values are expressed as mean ± SEM; ^**P < 0.01 when compared to normal control group, ^$$P < 0.01, ^$P < 0.05, when compared to OVX and ^##P < 0.01, ^#P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnet’s multiple comparison test).
A	Normal Control	2.210 ± 0.06	0.680 ± 0.035
B	OVX Control	3.267 ± 0.123^**	0.872 ± 0.047^**
C	OVX + OLZ Control	3.350 ± 0.161^**	0.944 ± 0.045^**
D	OVX + TEL	2.382 ± 0.110^$$	0.723 ± 0.025^$
E	OVX + OLZ + TEL	2.367 ± 0.096^##	0.797 ± 0.032^#

Table 3. Effect of Telmisartan on Liver and Kidneys Weight

Group

Treatment

Liver weight

Kidney weight

n = 6; The values are expressed as mean ± SEM; ^**P < 0.01 when compared to normal control group, ^$$P < 0.01, ^$P < 0.05, when compared to OVX and ^##P < 0.01, ^#P < 0.05 when compared to OVX + OLZ (One way ANOVA followed by Dunnet’s multiple comparison test).

Normal Control

2.210 ± 0.06

0.680 ± 0.035

OVX Control

3.267 ± 0.123^**

0.872 ± 0.047^**

OVX + OLZ Control

3.350 ± 0.161^**

0.944 ± 0.045^**

OVX + TEL

2.382 ± 0.110^$$

0.723 ± 0.025^$

OVX + OLZ + TEL

2.367 ± 0.096^##

0.797 ± 0.032^#